Description
JNJ-42165279 is a fatty acid amide hydrolase (FAAH) inhibitor developed by Janssen Pharmaceutica and IC50 value is 70 nM. It is described as a covalently binding but slowly reversible selective inhibitor of FAAH. Phase II human trials for the treatment of anxiety disorders and major depressive disorder is on-going